CARA THERAPEUTICS INC (CARA)

Company Profile

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 55 full-time employees. The company went IPO on 2014-01-31. The firm is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. The company is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. The company is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. The company has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Company Info

CARA THERAPEUTICS INC

400 Atlantic Street, Suite 500

Stamford CONNECTICUT 06902

P: 12034063700

CEO: Derek Chalmers

Employees: 55

Website: https://www.caratherapeutics.com/